If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
217
results.
Updated on
06/06/2025 [06:53:00]
Results 25 to 50 of 217
Absstract of: CN120078734A
本发明提供了一种用于核酸药物递送的脂质纳米颗粒组合物及其制备方法和应用。本发明提供的脂质纳米颗粒组合物包含类固醇‑阳离子脂质化合物、中性磷脂、和聚乙二醇脂质三种脂质成分。混合制备的组合物具有较佳的稳定性和转染效率。利用将脂质纳米颗粒用于递送核酸，例如mRNA，可以高效稳定的将核酸药物递送至靶细胞或器官，在实验动物体内可引起较高的特异性抗体应答，且化合物具有更好的安全性。
Absstract of: CN118079027A
The invention relates to the field of nano-drugs, in particular to a bionic nano-system with multiple targeting characteristics and co-drug loading and application of the bionic nano-system in glioma collaborative treatment. The invention constructs a nano-drug delivery system Ang2-Pmsc-NPs with central targeting and co-drug loading, and the nano-drug delivery system Ang2-Pmsc-NPs has a good cross-BBB transport characteristic and a good permeability characteristic of tumor tissues. According to the present invention, with the application of the siRNA treatment gene and the PROTAC molecule, the GSCs can be killed, the NAD < + > energy metabolism pathway of the tumor can be inhibited, the multi-target anti-glioma effect can be achieved, and the new idea and the experimental basis can be provided for the nano-drug treatment of the glioma.
Absstract of: AU2023366039A1
The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.
Absstract of: CN120078736A
本发明属于医药技术领域，公开了一种负载神经生长因子的仿生普鲁士蓝纳米制剂，为壳核结构，其内核为包覆有聚多巴胺涂层的普鲁士蓝纳米颗粒，在聚多巴胺涂层表面负载有神经生长因子；其外壳为仿生杂化膜。利用仿生杂化膜延长半衰期的特点，实现药物在病变部位的富集和缓慢释放；利用神经生长因子促骨生成和普鲁士蓝抗氧化两种不同机理的抗骨质疏松效应，辅助以纳米载体和仿生系统，实现骨质疏松症防治效果的最大化。还公开了其制备方法和在制备预防和/或治疗骨质疏松症药物中的应用。解决了骨质疏松症中成骨能力受损的根本问题，实现骨质疏松症部位的药物高度富集，为开发新型防治骨质疏松症的药剂及相关预防和治疗提供新理论支持。
Absstract of: CN120078738A
本发明提供了一种具有器官和细胞双重特异性靶向的聚合物脂质杂化纳米颗粒，包括：阳离子聚合物，辅助脂质，胆固醇和聚乙二醇衍生脂质，所述阳离子聚合物包括由聚乙烯亚胺和对甲苯磺酰基精氨酸制备得到的共聚物，所述阳离子聚合物在所述聚合物脂质杂化纳米颗粒中的摩尔百分比为10％～50％。本发明提供的聚合物脂质杂化纳米颗粒具有优异的器官和细胞靶向性，能够将功能mRNA特异性递送到脾脏不同的免疫细胞。
Absstract of: CN120078740A
本发明公开了一种基于铁蛋白纳米平台的毛细胞保护剂及其治疗听力损失的应用，属于生物医药领域，本发明的负载升麻素的铁蛋白纳米粒，包括作为载体的铁蛋白(Fn)和负载在铁蛋白中的升麻素(Ci@Fn)。通过将升麻提取物升麻素(Cimifugin，Ci)负载于铁蛋白中，赋予其额外的抗炎和组织保护功能，从而实现更精准、有效的治疗效果。Ci@Fn经耳后圆窗膜(RWM)注射后，随着外淋巴和内淋巴液的流动被输送到基底膜，最终靶向内耳毛细胞(HCs)。Ci@Fn进入毛细胞后，被溶酶体摄取并降解，释放出升麻素(Ci)，从而发挥对毛细胞的保护作用。
Absstract of: CN120081892A
本发明提供了一种具有式(I)所示结构的可电离阳离子脂质化合物，其可用于制备用于递送治疗剂和/或预防剂的脂质纳米颗粒(LNP)。利用本发明的可电离阳离子脂质化合物制备的LNP具有较佳的稳定性和转染效率，可以高效地、稳定地将生物活性物质(包括核酸，例如mRNA)递送至靶细胞或器官，从而在体内引起高特异性抗体应答。#imgabs0#
Absstract of: CN120078857A
本发明属于中药组合物技术领域，特别涉及一种抗HPV病毒的中药组合物及其相关应用。作为HPV感染的治疗和预防用药，该中药组合物以清热解毒、透毒外出、祛瘀生新为主要治则，包括以下原料：青黛、黄连、虎杖、滑石、黄芪、甘草、石见穿、皂角刺、白芨、木瓜、血竭和冰片。本发明组合物在临床上运用5余年，发现其具有很好清除宫颈、阴道高危型HPV感染的作用，临床局部用药3~6个月可以达到80%以上的清除率，说明该中药组合物具有抗HPV病毒作用，该中药组合物经纳米材料包裹后，在有效保护活性物分子的同时缓慢持续发挥功效，有效清除宫颈，发挥抗HPV病毒作用。
Absstract of: CN120078915A
本发明属于医学成像技术领域，具体涉及一种脑靶向APP@Dextran‑Fe3O4纳米颗粒及其制备方法和应用。本发明所提供的APP@Dextran‑Fe3O4纳米颗粒可通过非侵袭的静脉注射方式作用于脑内的β淀粉样蛋白受体，从而实现跨血脑屏障转运，并且在阿尔茨海默病患者的脑内具有更高的积累作用，尤其是在阿尔茨海默病主要的病变部位海马处异常累积，结合MPI成像高分辨率、高灵敏度的特点可实现阿尔茨海默病的诊断。同时病理分析发现APP@Dextran‑Fe3O4纳米颗粒具有抑制阿尔茨海默病脑内炎症反应，减少神经元细胞凋亡作用，对减缓阿尔茨海默病具有一定的益处。
Absstract of: CN120082547A
本公开提供一种用于自复制mRNA的加帽类似物及其应用，所述用于自复制mRNA的加帽类似物能够提高自复制mRNA的稳定性和/或自复制mRNA的翻译效率。
Absstract of: WO2025110774A1
The present invention relates to a nanoparticle carrier and an antiviral composition comprising same, the nanoparticle carrier comprising: gold nanoparticles; antisense oligonucleotides (ASOs) that complementarily bind to conserved RNA sequences derived from a viral genome; and ribonuclease H (RNase H) that binds to the ASOs to induce the cleavage of mRNA. The nanoparticle carrier and the antiviral composition comprising same can reduce mRNA expression of a virus by RNase H, and in particular, can have the effect of treating infectious diseases caused by a virus.
Absstract of: WO2025110773A1
The present invention relates to a gold nanoparticle carrier or a pharmaceutical composition for the prevention or treatment of cancer comprising the same, wherein the gold nanoparticle carrier includes gold nanoparticles, an antisense oligonucleotide (ASO) bound to the surface of the gold nanoparticles and binding specifically to a cancer-causing mutant gene, and an aptamer specific for a protein expressed by cancer cells.
Absstract of: WO2025110616A1
The present disclosure relates to a method for manufacturing a nanobubble-based drug carrier using focused ultrasound technology and a nanobubble-based drug carrier manufactured thereby and, more specifically, to a method for manufacturing a drug carrier containing a shell, with drugs and nanobubbles encapsulated inside the shell, using focused ultrasound technology, and a nanobubble-based drug carrier manufactured thereby.
Absstract of: WO2025110550A1
The present invention relates to a nucleic acid-based drug delivery platform. A complex according to the present invention has moderated toxicity and exhibits stable nucleic acid-binding ability due to osmotic activity. In addition, the complex promotes cell uptake of the nucleic acid supported on a polymer, and improves an endosomal release effect of the nucleic acid through degradation of nanoparticles in the cytoplasm. The complex according to the present invention has effects of maximizing gene expression of nucleic acids in a cell and contributing to maintaining the expression for a long time, and thus can be applied to various fields of immune activity, vaccine development, and the like.
Absstract of: WO2025110168A1
Problem To make available a silicate mineral having an average particle size larger than several hundred nm without containing impurities such as crystalline silica. Solution The content of crystalline silica and asbestos is 0.1 wt% or less in the silicate mineral of the present invention. The mineral preferably contains a carbonate and preferably has an average particle size of 100 nm or more. In addition, the mineral is suitably used in cosmetics, sanitary goods, pharmaceuticals, and foods. The silicate mineral is obtained by subjecting a natural silicate mineral to warm water or hot water treatment or hydrothermal reaction treatment at a pH of 9.4 or less.
Absstract of: WO2025109567A1
Provided herein are emulsion composition comprising a medium chain triglyceride (MCT), preferably tricaprilin. Also, described here are additional ingredients that make these emulsion compositions more suitable for oral intake, such as one or more emulsifiers, buffers such as phosphate buffers, as well as optionally glycerol and a sweetener and/or a flavoring agent. Described herein are methods of making and using these emulsions. The emulsions described may be used for oral administration of tricaprilin to treat and/or prevent various diseases or disorders.
Absstract of: WO2025108158A1
Provided are a celecoxib nanocrystal injection, a preparation method therefor, and use thereof, belonging to the field of pharmaceutical formulations. The provided celecoxib nanocrystal injection comprises celecoxib nanocrystals, a wetting agent, a stabilizer, and an osmotic pressure regulator. Moreover, the average particle diameter of the celecoxib nanocrystals is 100-500 nm. Optionally, the celecoxib nanocrystal injection further comprises a pH regulator and/or a lyoprotectant. After intravenous injection, the provided celecoxib nanocrystal injection can be rapidly dissolved in plasma, so that the application expectation of rapid onset of action in clinical acute pain management can be met. The celecoxib nanocrystal injection is prepared by adopting a combined technique of ball milling method and high-pressure homogenization. The ball milling method can process the micron-sized raw materials to the nanoscale, which can be further processed to a target particle diameter by high-pressure homogenization.
Absstract of: WO2025108355A1
A nucleic acid delivery carrier composition and use thereof. The composition comprises a cationic lipid, a helper phospholipid, cholesterol, and a PEG-conjugated lipid having a molar ratio of (30-50):(4-16):(31.5-63.5):(0.5-2.5); the helper phospholipid is one or a combination of two of DOPE and DSPC, and the cationic lipid is one or a combination of more structures selected from the following structures. The composition can wrap mRNA used for protein expression to treat related deficiency diseases, is efficient, and does not have toxic side effects.
Absstract of: WO2025108351A1
An ophthalmic cyclosporine nano-micelle drug, a preparation method therefor, and use thereof. The cyclosporine nano-micelle drug comprises: 0.1-10 parts by weight of a solubilizer for forming micelle particles, and 0.01-1 part by weight of cyclosporine loaded in the micelle particles. The solubilizer is a first solubilizer, or a combination of the first solubilizer and a second solubilizer.
Absstract of: WO2025107185A1
The present invention relates to the field of targeted therapy technology, and particularly, to a carrier, a targeted nanoparticle, a method for preparing same, and use thereof. The carrier disclosed in the present invention comprises tocilizumab grafted with a terminal carboxyl group-containing dye. The targeted nanoparticle comprises a carrier and a CO-release molecule. The carrier encapsulates the CO-release molecule to form a core-shell structure. In the targeted nanoparticle based on tocilizumab, the carrier is constructed by grafting the terminal carboxyl group-containing dye, and the carrier encapsulates the CO-release molecule. The carrier possesses a targeting effect, and the photothermal effect of the carrier can achieve the regulated CO release by NIR laser or targeted and controllable CO release under free radical stimulation, thereby achieving exogenous/endogenous dual-response release of CO. The present invention features good application prospects.
Absstract of: CN120059980A
本发明公开了一种EV衍生的工程化纳米膜囊泡的制备方法和应用，属于工程化纳米膜囊泡技术领域。本发明将来源于天然的膜组分和不同种类的脂质体通过膜融合的手段制备工程化的纳米囊泡载体，对生物活性分子RNA、DNA能够有效的装载和递送，有效发挥核酸纳米药物对细胞屏障的跨越功能，解决了传统磷脂类脂质体缺乏生物相容性和天然囊泡稳定性的弊端，该方法操作简单，处理样品量大，具有非常好的应用前景。
Absstract of: WO2024094211A1
The present invention relates to mucosal drug delivery systems, and specifically to a lipid composition; the lipid composition containing a therapeutic agent and/or prophylactic agent such as RNA can be used for mucosal delivery of the therapeutic agent and/or prophylactic agent to treat or prevent disease such as infectious disease.
Absstract of: CN120058695A
本发明公开了具有荧光“点亮”特性的自由基型光敏剂及其制备方法与应用。以4,7‑二溴‑2,1,3‑苯并噻唑与三苯胺衍生物为原料，通过Suzuki偶联反应得到中间产物1；将所得中间产物1和4‑氨基苯硼酸频哪醇酯进行Suzuki偶联反应得到中间产物2；将所得中间产物2和马来酸酐通过反应得到最终产物。本发明优点包括：将具有对Cys特异性识别且本身为强电子受体的马来酰亚胺引入到光敏剂分子骨架中，实现了光敏剂特异性识别Cys而被荧光“点亮”和提高自由基型ROS产生效率，对癌细胞具有良好的光动力治疗效果。
Absstract of: CN120053400A
本发明涉及纳米材料技术领域，具体涉及一种纳米自噬诱导制剂及其制备方法和应用、药物组合物；该纳米自噬诱导制剂包括具有核壳结构的复合材料和固定在所述复合材料上的能通过光解生成NO的物质；复合材料中，核为咖啡酸修饰的上转换纳米颗粒，壳为MOFs材料；所述MOFs材料金属中心为铜离子，有机配体选自羧酸类有机配体中的一种或多种。该纳米自噬诱导制剂拥有光和价态转换功能，在近红外光激发下产生UV，使得Cu2+还原为Cu+，能够释放羧酸类有机配体和还原后的Cu+，能通过光解生成NO的物质光解生成NO，可用于诱导过度自噬，为对抗肿瘤进展提供了强有力的协同抗肿瘤光免疫治疗效果。
Nº publicación: CN120053670A 30/05/2025
Applicant:
北京石油化工学院
Absstract of: CN120053670A
本发明公开了透明质酸疏水材料、透明质酸疏水自组装纳米复合材料及其制备方法，属于药物载体制备技术领域。本发明提供的一种透明质酸疏水材料的制备方法，包括以下步骤：以N,N‑二甲基甲酰胺为溶剂，加入C15~C25长链脂肪酸、N,N'‑二环己基碳二亚胺、4‑二甲氨基吡啶，调节pH为9~10，得到有机相溶液；以水为溶剂，加入透明质酸和吐温类表面活性剂，搅拌均匀得到水相溶液；将水相溶液和有机相溶液混合，水相溶液中的透明质酸的羟基与疏水型羧酸化合物中的羧基发生酯化反应，反应结束后利用醇沉法得到透明质酸疏水材料。
BOPI
Electronic site
